603368 柳药集团
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入5,377,2721.13%20,926,27121,182,45420,811,90319,052,831
减:营业总成本5,065,1651.86%20,015,83120,166,80619,726,39318,126,741
    其中:营业成本4,755,6311.66%18,614,57618,774,82318,337,66516,860,778
               财务费用40,654-20.17%217,888235,205249,462220,168
               资产减值损失----(14,201)------
公允价值变动收益------------
投资收益1,109-87,899.74%(52)(95)(706)7,412
    其中:对联营企业和合营企业的投资收益(1)-10.84%248(132)(715)(189)
营业利润275,809-11.03%882,3851,003,5981,043,683890,061
利润总额273,143-12.04%869,9421,003,1361,043,381890,401
减:所得税费用47,68945.16%149,405135,602136,777131,426
净利润225,454-18.81%720,536867,534906,604758,976
减:非控股权益868144.24%11,07312,66257,01257,458
股东净利润224,586-19.02%709,464854,872849,592701,518

市场价值指针
每股收益 (元) *0.640-8.57%1.7902.2102.3501.940
每股派息 (元) *----0.6800.7510.6000.508
每股净资产 (元) *19.7711.75%19.32719.11017.84716.057
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容